Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive soon after receiving positive results from a US 510(k) animal pilot study, indicating that CelGro® facilitates superior nerve regeneration when compared to the market-leading nerve repair device - restoring the sciatic nerve to a pre-injured state. As a result of this breakthrough nerve regeneration data, and in light of the previously released interim human clinical data, the company is evaluating the medical device US regulatory pathways to identify opportunities for expedited approval of CelGro® and the ideal route to the highest reimbursement value.
Orthocell identifying opportunities for expedited approval of CelGro after 'breakthrough' results
